替吉奥联合胸腔化疗治疗老年非小细胞肺癌合并胸腔积液临床疗效观察

Clinical study of combined therapy of S-1 and cisplatin for elderly advanced non-small cell lung cancer with pleural effusion

目的观察替吉奥（S-1）联合胸腔化疗治疗合并胸腔积液的老年非小细胞肺癌临床疗效和安全性。方法 36例老年非小细胞肺癌合并胸腔积液患者,应用中心静脉导管胸腔穿刺置管引流,胸腔内注入顺铂40 mg.m-2行胸腔化疗,每周1次,连用3周;同时给予替吉奥40~60 mg.m-2,口服bid,d1~14,21 d为1周期。至少完成2个周期,按照WHO标准评价客观疗效和不良反应。结果 36例入组患者疗效均可评价,CR 5.56%,PR 41.6%,NR 50%,不良反应主要是Ⅰ~Ⅱ胃肠道反应、血液学毒性,严重的骨髓抑制发生率较低。结论 （S-1）联合顺铂治疗老年非小细胞肺癌合并胸腔积液疗效好、不良反应小,值得临床推广应用。

[ Objective ] To evaluate the efficacy and safety of （S-l） capsule combined with cisplatin in the treatment of elderly advanced non-small cell lung cancer with pleural effusion patients. [ Methods ] 36 patients accepted chemotherapy with （S-1）（40-60 mg·m-2 ,po bid d1-14 ） and cisplatin（40 mg· m-2 into the thoracic cavity, once weekly for 3 weeks）. The efficacy and adverse effects were evaluated after two cycles according to the common toxicity criteria of WHO.[ Resluts ] All 36 patients could be given an objective evaluation of the efficacy and safety. 2 cases of CR（5.56%）, 15 cases of PR（41.6%）, 18 cases of （NC ＋ PD） （50%）, the objective response rate（CR＋PR） was 47.2% （17/36）.The main adverse reactions included Ⅰ～Ⅱ gastrointestinal reactions and haematology toxicity, and less myelosuppression was found. [ Conclusion ] The therapy of （S-1） and cisplatin for elderly advanced non-small cell lung cancer with pleural effusion is is safe and effective, it is worthy of studying further in clinic.